GRIFOLS S A/S (NASDAQ:GRFS) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a sell rating to a hold rating in a report released on Saturday, ValuEngine reports.

Other research analysts have also recently issued research reports about the company. Morgan Stanley restated an overweight rating on shares of GRIFOLS S A/S in a research note on Tuesday, June 23rd. BidaskClub cut GRIFOLS S A/S from a buy rating to a hold rating in a research note on Thursday, May 28th. JPMorgan Chase & Co. cut GRIFOLS S A/S from an overweight rating to a neutral rating in a research note on Tuesday, April 21st. Kepler Capital Markets restated a hold rating on shares of GRIFOLS S A/S in a research note on Friday, March 27th. Finally, Citigroup cut GRIFOLS S A/S from a neutral rating to a sell rating in a research note on Tuesday, June 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $24.00.

Shares of NASDAQ:GRFS opened at $18.24 on Friday. The stock has a fifty day simple moving average of $19.57 and a two-hundred day simple moving average of $21.38. The stock has a market capitalization of $12.88 billion, a price-to-earnings ratio of 16.29, a PEG ratio of 0.99 and a beta of 0.83. GRIFOLS S A/S has a 12-month low of $13.40 and a 12-month high of $25.73. The company has a current ratio of 2.75, a quick ratio of 0.90 and a debt-to-equity ratio of 0.95.

GRIFOLS S A/S (NASDAQ:GRFS) last announced its quarterly earnings data on Tuesday, April 21st. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.01. The business had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.40 billion. GRIFOLS S A/S had a return on equity of 11.92% and a net margin of 13.31%. As a group, equities research analysts predict that GRIFOLS S A/S will post 1.36 EPS for the current year.

Institutional investors have recently bought and sold shares of the stock. FMR LLC increased its position in GRIFOLS S A/S by 185.7% during the fourth quarter. FMR LLC now owns 25,886 shares of the biotechnology company’s stock valued at $603,000 after acquiring an additional 16,825 shares during the last quarter. Two Sigma Advisers LP increased its position in GRIFOLS S A/S by 17.0% during the first quarter. Two Sigma Advisers LP now owns 388,700 shares of the biotechnology company’s stock valued at $7,828,000 after acquiring an additional 56,600 shares during the last quarter. JPMorgan Chase & Co. increased its position in GRIFOLS S A/S by 33.2% during the first quarter. JPMorgan Chase & Co. now owns 660,551 shares of the biotechnology company’s stock valued at $13,303,000 after acquiring an additional 164,526 shares during the last quarter. Norges Bank bought a new stake in GRIFOLS S A/S during the fourth quarter valued at about $70,212,000. Finally, BNP Paribas Arbitrage SA grew its holdings in GRIFOLS S A/S by 248.7% during the first quarter. BNP Paribas Arbitrage SA now owns 99,154 shares of the biotechnology company’s stock valued at $1,997,000 after purchasing an additional 70,716 shares during the period. Institutional investors own 17.88% of the company’s stock.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Read More: What is Considered a Good Return on Equity (ROE)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.